{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"8.0","value":"5.1"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"9.4","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"NPF failure was defined as tumor recurrence within the neuroaxis but outside the radiation therapy clinical target volume (CTV). The cumulative incidence (CI) of NPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., LPF failure) and with other events prior to NPF failure (e.g., death, second malignancy) were considered as having competing events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V).","id":"OG000","title":"Involved Field Radiation (IFRT)"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI).","id":"OG001","title":"Posterior Fossa Radiation (PFRT)"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable patients 3-21 yrs of age are included. Patients with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). Arms I/III/V \\[IFRT\\] are combined \\& arms II/IV/VI \\[PFRT\\] are combined. 26 \\& 23 IFRT \\& PFRT pts were NE and were excluded, leaving 227 and 237 eligible and evaluable pts.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Non-posterior Fossa (NPF) Failure Rate","type":"SECONDARY","unitOfMeasure":"Percentage of 3 yr cumulative incidence"}